R&D Personalized medicine: DYNAPRED – History
Dynakin’s in-house R&D experts work on the design of software (that can be included in devices or used as a web-based stand-alone) that package Dynakin’s acquired knowledge on the PK and PD of the drug, also leveraging the public domain, all included in mixed effects models developed in-house. The models are Integrated within Dynakin’s own maximum likelihood algorithm (including a Bayes estimator option) in turn residing within a .NET server based application or within a dosing device (pump, etc). The goal is titration of individual patients’ dose to their individual therapeutic target. Complete individualization of the dose in each patient is achieved by development for each TA by Dynakin of mixed effects models including specific predictors of the variability (e.g. demographics, disease related, genetic polymorphisms, etc.) and the use of a monitoring blood sample. The outcome of the use of these products is improved quality of life for the patients, reduction in health expenditures and improvement of the market image for the drug.